BioSpace News Archive

Skanska and its joint venture partner, HGR General Contractors, signed a contract with The University of Texas at Tyler to build a medical education building in Tyler, Texas, USA.

Pfizer Inc. announced positive top-line results from the Phase 3 BENEGENE-2 study evaluating fidanacogene elaparvovec, an investigational gene therapy, for the treatment of adult males with moderately severe to severe hemophilia B.

Procaps Group, S.A., a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced that it will present at the 2023 J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 8:00 am PST.

Amyris, Inc. announced that it has entered into a definitive purchase agreement for the purchase and sale of 20,000,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 15,000,000 shares of common stock in a registered direct offering.

ALR Technologies SG Ltd., the diabetes management company, announced the completion of a long-term manufacturing and supply agreement with Infinovo Medical Co. Ltd for the Continuous Glucose Monitor hardware used in the GluCurve Pet CGM.

Acer Therapeutics Inc. announced that The Nasdaq Stock Market LLC has formally notified Acer that the company has regained compliance with the $35 million market value of listed securities requirement, and otherwise satisfies all other criteria necessary, for continued listing on The Nasdaq Capital Market.

Outlook Therapeutics, Inc. announced its financial results for its fiscal year ended September 30, 2022, and provided recent corporate highlights.

Coya Therapeutics, Inc. announced the pricing of its initial public offering of 3,050,000 shares of its common stock and accompanying warrants to purchase up to 1,525,000 shares of common stock.

AB Science SA announced that its Phase III clinical trial in progressive forms of multiple sclerosis has been approved by the US Food and Drug Administration.

Vericel Corporation, a leader in advanced therapies for the sports medicine and severe burn care markets, announced that the U.S. Food and Drug Administration has approved NexoBrid® for the removal of eschar in adults with deep partial-thickness and/or full-thickness thermal burns.